| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032750595 |
| P356 | DOI | 10.1038/BJC.2012.312 |
| P932 | PMC publication ID | 3419960 |
| P698 | PubMed publication ID | 22805325 |
| P5875 | ResearchGate publication ID | 229159483 |
| P2093 | author name string | M J Egorin | |
| C Nabhan | |||
| T M Lestingi | |||
| J D Bitran | |||
| D Villines | |||
| J H Beumer | |||
| K Tolzien | |||
| S M Christner | |||
| T V Valdez | |||
| P2860 | cites work | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate | Q33184380 | ||
| Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors | Q33918083 | ||
| NCCN clinical practice guidelines in oncology: prostate cancer | Q34616548 | ||
| Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor | Q35788293 | ||
| Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer | Q35791273 | ||
| A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. | Q36610713 | ||
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia | Q36671633 | ||
| Sorafenib for the treatment of advanced renal cell carcinoma | Q36692604 | ||
| A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer | Q38461620 | ||
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 | ||
| In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. | Q40477521 | ||
| Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma | Q40582408 | ||
| A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer | Q43583678 | ||
| Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients | Q44780594 | ||
| Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects | Q44892834 | ||
| Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer | Q45018087 | ||
| A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer | Q45076471 | ||
| Mechanisms of androgen-refractory prostate cancer | Q45094999 | ||
| A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy | Q46041319 | ||
| Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study | Q46369839 | ||
| Metabolism and disposition of imatinib mesylate in healthy volunteers | Q46592261 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 | ||
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer | Q46825505 | ||
| A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer | Q46868463 | ||
| Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases | Q46972241 | ||
| Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation | Q48292912 | ||
| Her wedding. | Q53378194 | ||
| Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. | Q54598136 | ||
| Gene expression correlates of clinical prostate cancer behavior | Q60156349 | ||
| Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas | Q71652817 | ||
| Response evaluation criteria in solid tumors (RECIST): new guidelines | Q74245275 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | imatinib | Q177094 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 592-597 | |
| P577 | publication date | 2012-07-17 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer | |
| P478 | volume | 107 |
| Q34548719 | Ageing is a risk factor in imatinib mesylate cardiotoxicity |
| Q34353130 | Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth |
| Q38094296 | Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. |
| Q36270115 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review |
| Q38116358 | Novel therapeutic approaches for the treatment of castration-resistant prostate cancer |
| Q38897955 | Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer |
| Q27022567 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer |
| Q42530532 | Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. |
| Q39401758 | The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer |
Search more.